Contact

Rheumatology Authority serves as a reference resource covering the full scope of rheumatologic disease, diagnostics, treatment frameworks, and specialist training pathways. This page explains how to reach the editorial office, what geographic scope the resource covers, what information to include in a message, and what response timelines to expect. Understanding these parameters helps ensure that inquiries are routed and addressed efficiently.

How to reach this office

All inquiries directed to Rheumatology Authority are handled through the site's contact form, accessible on this page. The editorial office does not publish a direct telephone line, as written correspondence allows for accurate documentation and proper routing of questions to the appropriate subject-matter reviewers.

Three categories of inquiry are accepted:

1. Editorial and factual corrections — If a page contains an outdated citation, a misattributed source, or a factual error relative to a named public standard (such as an ACR guideline or a regulatory reference from the FDA's Center for Drug Evaluation and Research), corrections are prioritized and reviewed within the editorial workflow.
2. Content gap requests — Requests to cover a specific rheumatologic condition, diagnostic protocol, or subspecialty topic that is absent from the existing library.
3. Licensing and republication inquiries — Questions about the terms under which reference content may be cited, excerpted, or reproduced in academic, clinical, or institutional contexts.

The editorial office does not provide personalized medical advice, diagnostic assessments, or treatment recommendations. Rheumatology Authority is a reference-grade informational resource, not a clinical service. Individuals seeking guidance on specific symptoms or conditions should consult a board-certified rheumatologist; the page Signs You Should See a Rheumatologist and How to Get Help for Rheumatology describe that pathway in structured detail.

Service area covered

Rheumatology Authority is a nationally scoped US resource. Content is calibrated to the regulatory and clinical standards applicable across all 50 US states, with primary reference to federal-level frameworks including guidelines issued by the American College of Rheumatology (ACR), the Centers for Disease Control and Prevention (CDC) for arthritis epidemiology data, and the FDA for biologic and DMARD approval statuses.

Where state-level variation is clinically relevant — for example, in Medicaid coverage of biologic therapies such as TNF inhibitors or JAK inhibitors — content notes jurisdictional differences without asserting a single national standard. The Regulatory Context for Rheumatology page maps the principal federal oversight bodies and frameworks in detail.

International visitors access the resource, but content is not calibrated to the standards of the European Medicines Agency (EMA), NICE (UK), or provincial Canadian health authorities. Readers outside the US should treat diagnostic criteria and treatment classifications as US-specific references and consult nationally relevant clinical bodies for local applicability.

What to include in your message

A well-structured message reduces processing time and improves the accuracy of any editorial response. Messages should include the following 5 elements:

1. Page URL or title — Identify the specific page being referenced, such as Biologic Therapies or Blood Tests for Autoimmune Disease.
2. Nature of the inquiry — State clearly whether the message concerns a factual correction, a content gap, a licensing question, or another category.
3. Source citation for corrections — If flagging a factual error, include the named public source that contradicts the published content. Named sources include ACR clinical practice guidelines, CDC surveillance reports, FDA drug labels or approval letters, or peer-reviewed publications indexed in PubMed.
4. Specific passage — Quote the exact sentence or data point in question rather than referencing a general topic area.
5. Contact information — Provide a valid email address so the editorial team can respond directly.

Messages that omit the page reference or fail to specify a named source for corrections cannot be prioritized and may receive a delayed or generalized response.

Response expectations

Editorial correspondence is reviewed on a standard queue. Messages flagged as factual corrections referencing a named public source — such as a discrepancy against an ACR guideline updated within the prior 24-month window — receive priority review, typically within 5 to 7 business days. Content gap requests and licensing inquiries are reviewed on a secondary queue with a target response window of 10 to 14 business days.

The editorial office does not guarantee publication of requested topics. Content decisions are governed by the site's coverage framework, which prioritizes topics with documented clinical relevance, a named regulatory or standards-body anchor, and sufficient public-source documentation to meet the site's reference-grade accuracy standard.

Responses to licensing and republication inquiries will address permissible use conditions. Content derived from named third-party sources — including ACR guidelines, NIAMS disease fact sheets, or FDA labeling — is subject to the terms of those originating institutions, and Rheumatology Authority cannot grant broader republication rights than those held under fair use and standard journalistic citation practice.

Messages submitted through the contact form are not transmitted to any clinical provider network and do not constitute a medical inquiry, referral request, or patient record. No personally identifiable health information should be included in editorial correspondence.

Privacy Policy

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)